lung cancer

News

Roche's Tecentriq gains new US lung cancer indication

Roche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it a licence in a difficult to treat form of lung cancer in combination wi

News

Lilly's Cyramza hits mark in first-line lung cancer trial

Eli Lilly has produced phase 3 data that supports use of its Cyramza combined with Roche's Tarceva in first-line non-small cell lung cancer with EGFR mutations, paving the way for filings w

News

Two new cancer Priority Reviews for Roche

Roche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung cancer medicine entrectinib and lymphoma treatment polat

News

J&J pays $3.4 billion for robotics firm Auris

Johnson & Johnson’s rumoured interest in Auris Health has been confirmed with a $3.3 billion buyout deal that boosts the group’s position in the fast-growing surgical robotics market.

News

BMS pulls Opdivo/Yervoy in first-line lung cancer

Bristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line lung cancer market dominated by rival Merck & Co.

News

FDA extends review of Merck & Co's Keytruda in lung cancer u...

US regulators have pushed back the deadline for their review of Merck & Co’s immunotherapy Keytruda in certain patients with untreated lung cancer, after the pharmaceutical company subm

Roche's Tecentriq gains new US lung cancer indication

Lilly's Cyramza hits mark in first-line lung cancer trial

Two new cancer Priority Reviews for Roche

J&J pays $3.4 billion for robotics firm Auris

BMS pulls Opdivo/Yervoy in first-line lung cancer

FDA extends review of Merck & Co's Keytruda in lung cancer u...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

lung cancer

Editor's Picks